AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
257.04
+0.94 (0.37%)
Jul 22, 2026, 10:17 AM EDT - Market open
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,102,088
Profits / Employee
$63,070
Market Cap
454.14B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | 0 | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 3 hours ago - AbbVie price target raised to $282 from $273 at Canaccord - TheFly
- 5 days ago - AbbVie’s Allergan Aesthetics receives approval for Boey in Europe - TheFly
- 5 days ago - Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients - PRNewsWire
- 7 days ago - AbbVie price target raised to $260 from $230 at Citi - TheFly
- 8 days ago - SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development - PRNewsWire
- 8 days ago - Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals - ETF Trends
- 8 days ago - AbbVie price target raised to $260 from $230 at UBS - TheFly
- 9 days ago - AbbVie price target raised to $300 from $258 at BMO Capital - TheFly